98%
921
2 minutes
20
Background: With the improvement in survival of hepatocellular carcinoma patients, extrahepatic metastases have become a more frequent complication. Although pathological fractures or paralysis due to bone metastases deteriorate the quality of life of patients, no treatment guideline for bone metastases has been established. This study aimed to clarify the risk factors for these events and the clinical course of patients with bone metastases.
Methods: Out of 783 hepatocellular carcinoma patients treated in our institution between 2009 and 2016, 76 patients with bone metastases were enrolled. They were divided into two groups by the trigger of bone metastases detection. One was those diagnosed by surveillance (surveillance group), and the other was those based on symptom presentation (non-surveillance group). We investigated the clinical features, risk factors for fractures or paralysis and prognostic factors for survival after bone metastases.
Results: Baseline characteristics and survival were not significantly different between two groups. Fractures or paralysis occurred in 10 patients (13.2%), and the frequency was significantly higher in the non-surveillance group (20.9%) than the surveillance group (3.0%) in univariate analysis (p = 0.036). The median survival after diagnosis of bone metastases was 11.7 months. Age over 75 years (p = 0.002), hepatitis C-virus etiology (p = 0.007) and Child-Pugh class B/C (p < 0.001) were significantly associated with a shorter survival in multivariate analysis, but fractures or paralysis did not affect the survival.
Conclusions: Early diagnosis through surveillance for hepatocellular carcinoma bone metastases may prevent fractures or paralysis and lead to a better quality of life for these patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/jjco/hyz028 | DOI Listing |
Cancer Manag Res
September 2025
The School of Clinical Medicine, Fujian Medical University, Fuzhou, Fujian, People's Republic of China.
Background: Lung cancer brain metastasis (LCBM) accounts for 40-50% of intracranial malignancies, with emerging evidence of alternative metastatic pathways circumventing the blood-brain barrier. Existing prognostic models lack validation in Asian populations and molecular stratification. This multicenter study aimed to develop a clinical nomogram integrating clinicopathological and molecular determinants for personalized LCBM management.
View Article and Find Full Text PDFIndian J Nucl Med
August 2025
Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Metastatic renal osteosarcoma is a rare entity. We report a case of a 52-year-old male postright nephrectomy status presented to us with metastatic renal osteosarcoma. 18-fluorine- fluorodeoxyglucose (F-FDG) avid lesions were seen in the right renal bed with extension to adjacent hepatic parenchyma.
View Article and Find Full Text PDFCureus
September 2025
Department of Medical Oncology, Faculty of Medicine, Pharmacy and Dental Medicine of Fez, University Sidi Mohamed Ben Abdellah, Hassan II University Hospital Center, Fez, MAR.
Introduction Breast cancer (BC) is the most common malignancy among women worldwide and the leading cause of cancer-related mortality in women in Morocco. However, there is limited evidence on survival outcomes and treatment patterns among elderly patients with metastatic breast cancer (MBC) in this setting. Methods We conducted a retrospective cohort study at the Department of Medical Oncology, Hassan II University Hospital in Fez.
View Article and Find Full Text PDFCureus
August 2025
Division of Radiation Oncology and Developmental Radiotherapeutics, BC Cancer - Vancouver, Vancouver, CAN.
Introduction In select tumor sites, symptom palliation and local control can be improved through delivering higher biological equivalent doses (BED) of radiotherapy. However, not all patients are suitable candidates for stereotactic body radiation therapy (SBRT). The 30 Grays in five fractions (30/5) regimen is a conformal, hypofractionated regimen that offers a higher BED compared to conventional palliative radiotherapy.
View Article and Find Full Text PDFRev Bras Ortop (Sao Paulo)
June 2025
Departamento de Ortopedia e Traumatologia, Faculdade de Medicina, Udayana University, Prof. Ngoerah General Hospital, Bali, Indonésia.
Objective: The present study explores the association between these inflammatory markers and metastasis in osteosarcoma patients.
Methods: We conducted a retrospective analysis of osteosarcoma patients at our center between January 2022 and August 2024. We collected the clinical and laboratory data of the patients, including white blood cell differential count, C-reactive protein (CRP) levels, erythrocyte sedimentation rate (ESR), neutrophil-to-lymphocyte ratio (NLR), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) levels.